VBI Vaccines receives grant to advance RSV candidate
RSV, a virus, infects the airways and lungs and can result in serious illness in both infants and elderly adults. The Centers for Disease Control and Prevention (CDC) have stated that nearly all children contract an RSV infection by 2 years old. Between 25 percent and 40 percent of these children manifest symptoms of bronchiolitis or pneumonia, and 2 percent need hospitalization.
The funds were granted from the National Research Council – Industrial Research Assistance Program (NRC-IRAP), a Canadian organization that receives sponsorship from the government. It offers business and technical advisory services and financial support for the creation and sale of novel technologies developed within Canada.
"Recent research suggests that the shape, or conformation, of the target proteins in an RSV vaccine may influence the potency and success of the candidate," David Anderson, VBI's senior vice president of research, said. "We are optimistic that by applying our eVLP Platform technology to RSV, we may contribute to the advancement of an improved RSV vaccine candidate. We are grateful to NRC-IRAP for their support in helping us advance this important research."